000 03599naa a22005417i 4500
001 UMUN-OA-20261005-MLS-039
003 local
005 20261005174904.0
006 m o d
007 cr||||||||||||
008 261005s2020 xx o u000 0 eng d
024 7 _a10.21037/atm-20-1855
_2doi
035 _a(local)EuropePMC:PMC7290560
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aAnna Maria Azzini
_eauthor.
245 1 2 _aA 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. /
_cAnna Maria Azzini; Romolo Marco Dorizzi; Piersandro Sette [and others].
264 1 _a[Place of publication not identified] :
_bAME Publications,
_c2020.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aBiomarkers to guide antibiotic treatment decisions have been proposed as an effective way to enhancing a more appropriate use of antibiotics. As a biomarker, procalcitonin (PCT) has been found to have good specificity to distinguish bacterial from non-bacterial inflammations. Decisions regarding antibiotic use in an individual patient are complex and should be based on the pre-test probability for bacterial infection, the severity of presentation and the results of PCT serum concentration. In the context of a high pre-test probability for bacterial infections and/or a high-risk patient with sepsis, monitoring of PCT over time helps to track the resolution of infection and decisions regarding early stop of antibiotic treatment. As outlined by the Evidence Based Laboratory Medicine (EBLM), not only the pre-test probability but also the positive likelihood ratio influence the performance of a test do be really diagnostic. This aspect should be taken into account in the interpretation of the results of clinical trials evaluating the performance of PCT in guiding antibiotic therapy.
540 _aCreative Commons Attribution-NonCommercial-NoDerivatives. See the linked licence for the applicable terms.
_uhttps://creativecommons.org/licenses/by-nc-nd/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aAntibiotic Therapy
650 4 _aProcalcitonin (Pct)
650 4 _aEvidence Based Laboratory Medicine (Eblm)
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _aclinical chemistry
655 4 _aReview articles.
700 0 _aRomolo Marco Dorizzi
_eauthor.
700 0 _aPiersandro Sette
_eauthor.
700 0 _aMarta Vecchi
_eauthor.
700 0 _aIlaria Coledan
_eauthor.
700 0 _aElda Righi
_eauthor.
700 0 _aEvelina Tacconelli
_eauthor.
773 0 _tAnnals of translational medicine
_gVol. 8, no. 9, (2020), pages/article 610
_x2305-5839
856 4 0 _uhttps://europepmc.org/articles/PMC7290560
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC7290560
_qlocal
942 _n0
999 _c1181
_d1181